Should countries bring critical drug production home?

TRADELABOR has more than 20 years of experience in the control and treatment of air, working with an experienced and qualified technical staff and with the most advanced technology in this area, which together guarantee the quality of the services provided.



Regulatory breaches at drug manufacturing sites in India and China have fuelled concerns over the safety of the API supply chain and sparked calls for countries to repatriate production of critical medicines. But is this a good idea? Two writers explore the pros and cons of taking back control of API manufacturing.

Continue at:

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:


Manostaxx – Industrial Management Consulting

Leave a Reply

Your email address will not be published. Required fields are marked *